STUDY OF ECULIZUMAB IN REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)SUBJECTS

Registry ID

EUCTR2013-003589-15

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Alexion Pharmaceuticals, Inc.

Start date

2014-02-25

Last update

2026-08-16

Conditions

• Generalized Myasthenia Gravis

Summary

Assess the efficacy of eculizumab as compared with placebo in the treatment of refractory gMG based on the improvement in the MG-specific Activities of Daily Living profile (MG-ADL).

Locations

• , , Germany
• , , Sweden
• , , UK
• , , Italy
• , , Spain
• , , Belgium
• , , Netherlands
• , , Denmark
• , , Greece
• , , Finland
• , , Hungary
• , , Czechia
• , , France

Related clinical trials

• A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
• An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
• An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
• A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
• Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

View on source registry